Neurocrine Biosciences (NBIX) Other Accumulated Expenses (2011 - 2026)

Neurocrine Biosciences' Other Accumulated Expenses history runs 16 years deep, the most recent figure standing at $58.7 million for Q1 2026.

• Quarterly Other Accumulated Expenses rose 23.06% year-over-year to $58.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $58.7 million (up 23.06% YoY) and the FY2025 annual result came in at $69.1 million, up 49.89% from the prior year.
• Other Accumulated Expenses was $58.7 million for Q1 2026 at Neurocrine Biosciences, down from $69.1 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $69.1 million in Q4 2025 and bottomed at $17.6 million in Q1 2022.
• A 5-year average of $36.3 million and a median of $36.7 million in 2024 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Other Accumulated Expenses declined 9.5% — and 2024, when it soared 99.46%.
• Neurocrine Biosciences' Other Accumulated Expenses stood at $20.7 million in 2022, then jumped by 73.43% to $35.9 million in 2023, then grew by 28.41% to $46.1 million in 2024, then soared by 49.89% to $69.1 million in 2025, then fell by 15.05% to $58.7 million in 2026.
• Business Quant data shows NBIX's Other Accumulated Expenses at $58.7 million in Q1 2026, $69.1 million in Q4 2025, and $53.7 million in Q3 2025.